Previously Published on Genprex.com — Genprex, Inc. (“Genprex” or the “Company”) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany.
Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline. – Disruptive gene therapy approach developed by University of Pittsburgh researchers may be a promising treatment for Type 1 and Type 2 diabetes.
The abstract data were released, and the presentation will be delivered on February 25th at 2:25 pm CET by Ranjeet S. Kalsi, DO, a member of the laboratory of George Gittes, MD, from Pitt’s Division of Pediatric Surgery, Pittsburgh, Pennsylvania. The complete presentation will be available on the Company’s website here following the close of Dr. Kalsi’s presentation.
The presentation titled, “Pancreatic Intraductal Infusion of Adeno-Associated Virus (AAV) to Treat Non-Human Primates in a Toxin-Induced Diabetes Model,” will report results from eight non-human primates (NHPs) with toxin-induced diabetes after streptozocin administration. They received a novel infusion process that used an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
Read the Full article here!